COVID-19: Information on ASPIRA LABS Operations

Click to Learn More

Providers

Improved Ovarian Cancer Risk Detection


It is well-recognized that the critical challenge in ovarian cancer is identifying it as early as possible in the work-up and getting patients to the proper care.

Studies show 20-40% of Ovarian Cancer Patients are Not Seen By a Gynecologic Oncologist


OVA1® can help to change this.

Although the number of women who have received a consultation with a gynecologic oncologist has increased in recent years, only 40% of those patients received guideline surgery and chemotherapy.1 This percentage is far below clinical recommendations and may explain the limited improvement in survival rates. Utilizing OVA1 in your practice helps to guide when a specialist should perform surgery.

Additionally, many women do not have a gynecologic oncologist within close proximity, limiting their access to care from a specialist.2  Utilizing OVA1 to identify high-risk patients can help to ensure these patients receive optimal care.

The evidence supporting stratifying patients to this optimal care pathway is reinforced in major medical society guidelines.

Ovarian Cancer Today


Over 22,500 women are diagnosed with ovarian cancer each year in the U.S. and it is estimated that about 14,000 women die annually from this disease3. According to the National Cancer Institute SEER Database, if a woman is diagnosed today, she has a 47.6% chance of living for another 5 years. While ovarian cancer diagnosis and treatment have come a long way, it remains the deadliest gynecologic cancer.

Medical Societies

Society of Gynecologic Oncology, National Comprehensive Cancer Network, The American College of Obstetricians and Gynecologists and National Institutes of Health Logos